USV Launches Jalra Trio for Management of Type 2 Diabetes in India

USV Pvt. Ltd, a leading drug manufacturer in the anti-diabetic segment, has announced the launch of the brand Jalra Trio for the treatment of patients with uncontrolled diabetes in India.

Jalra Trio is a fixed-dose combination tablet containing Vildagliptin 100 mg (Sustained Release), Dapagliflozin 10 mg, and Metformin 500 mg (Sustained Release) which is approved by DCGI.

Jalra Trio is priced affordably and is now available across India.

Jalra Trio is a valuable addition to the existing Jalra product range offered by USV to help Diabetes patients in India over the last decade.

Vildagliptin is a DPP-4 inhibitor, which stimulates insulin secretion & inhibits glucagon secretion in a glucose-dependent manner. Dapagliflozin is a SGLT2 inhibitor, which causes glucosuria thereby reducing blood glucose levels. In addition, dapagliflozin also possesses weight-lowering and BP-lowering effects. Metformin decreases hepatic glucose production & enhances insulin sensitivity by increasing peripheral glucose uptake and utilization.

Jalra Trio – a combination of Vildagliptin, Dapagliflozin, & Metformin is clinically advantageous due to its complementary mechanisms of action. All three agents do not increase the risk of hypoglycemia by virtue of their beta-cell-independent activity.

Jalra Trio could provide durable & sustained glycemic control of all parameters – FBG, PPG, and HbA1c. The single-pill combination reduces pill burden; thus, enhancing treatment adherence & patient compliance.

Diabetes remains a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. India is now the most populous country, and diabetes affects 74 million residents, representing 14% of the global disease burden. Most recent Indian studies have reported that 35% of patients with ‘diagnosed diabetes’ do not achieve glycemic control, across most states of India.

References

1. Jithin Sam Verghese, Ranjit Mohan Anajana, Diabetes diagnosis, treatment, and control in India: results from a national survey of 1.65 million adults aged 18 years and older, 2019-2021, Medriv, https://doi.org/10.1101/2023.02.06.23285544
2. WHO Fact Sheets, Diabetes April 2023, URL https://www.who.int/news-room/fact-sheets/detail/diabetes
3. Ahrén B, et al, Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011 Sep;13(9):775-83. doi: 10.1111/j.1463-1326.2011.01414.x. PMID: 21507182.
4. Albarrán OG, Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]. Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. Spanish. doi: 10.1016/S0025-7753(13)70062-9.
5. Rena G, The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3.